Compare Amphastar Pharmaceuticals Inc (AMPH) vs Abercrombie & Fitch Co. (ANF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Abercrombie & Fitch Co. — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Abercrombie & Fitch Co. trades at $118.27 (market cap $5.27B). The key difference: Abercrombie & Fitch Co. is far larger — about 6.1× Amphastar Pharmaceuticals Inc's market cap, and Abercrombie & Fitch Co. is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | ANF | |
|---|---|---|
Market Cap | $863.95M | $5.27B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $129.85 |
52-Week Low | $16.87 | $65.61 |
Enterprise Value | $1.26B | $5.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Abercrombie & Fitch (ANF) trades at $112.62, up 1.94% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 2025 revenue of $4.95B and net income of $566.22M, achieving consistent earnings beats in recent quarters. Valuation remains attractive with P/E of 10.89 and EV/EBITDA of 6.54, while profitability metrics show impressive ROE of 39.04% and net margin of 9.34%.
ANF presents a compelling investment case with strong operational performance and reasonable valuation, though technical indicators show overbought conditions. Key risks include retail sector volatility and potential growth headwinds in EMEA markets. Analyst consensus leans neutral with 50% hold ratings, while institutional ownership trends show continued interest from major funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Abercrombie & Fitch Co.
Abercrombie & Fitch Co is a specialty retailer that sells casual clothing, personal-care products, and accessories for men, women, and children. It sells direct to consumer through its stores and websites, which include the Abercrombie & Fitch, Abercrombie kids, and Hollister brands. Most stores are in the United States, but the company does have many stores in Canada, Europe, and Asia. All stores are leased. Abercrombie ships to well over 100 countries via its websites. The company sources its merchandise from dozens of vendors that are primarily located in Asia and Central America. Abercrombie has two distribution centers in Ohio to support its North American operations. It uses third-party distributors for sales in Europe and Asia.
Read more on ANF →
